CatalystMarker
← board

VNRX

distress 7/10 · high distress / dilution risk
$1.01-3%today-94% from 52w high
volition.com67 employeesHenderson, NVMedical Devices
Revenue
pre-revenue
Liquidity
$3M
Runway
0.1 yrs
Shares 1y
-92%

Price & events

-82.6% over 6M
$1.01$3.41$5.80Jan 26Apr 26Jul 2618.0Mdilution: EFFECT shelf_effective (2026-07-17)dilution: S-3 shelf_registration (2026-07-10)dilution: 424B5 offering (2026-06-09)dilution: 424B5 offering (2026-06-05)dilution: EFFECT shelf_effective (2026-02-19)dilution: S-3 shelf_registration (2026-02-09)financing: 8-K private_placement (2026-06-18)financing: 8-K material_agreement (2026-06-10)financing: 8-K material_agreement (2026-05-22)financing: 8-K private_placement (2026-02-20)rating: D. Boral Capital: Buy → Hold (2026-04-20)rating: HC Wainwright & Co.: Buy (2026-04-02)rating: D. Boral Capital: Buy (2026-03-31)rating: D. Boral Capital: Buy (2026-03-26)rating: D. Boral Capital: Buy (2026-03-18)
CatalystRating changeDilutionFinancingdashed = today
-2.9%
1D
-12.9%
1W
-16.5%
1M
-63.9%
3M
-82.0%
6M
-93.2%
1Y
-93.0%
2Y
-98.3%
5Y
-98.7%
All

Overview

Market Cap
$8.41M
Enterprise Value
$11.66M
Volume
21.55K
52 Week Range
$1.01 – $15.60
Total Shares
8.33M
Float Shares
6.66M
Short %
2.82%
% Held by Insiders
8.62%
% Held by Institutions
20.80%
RVOL
0.09x
Beta
1.11

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 8,330,270 · 6 offerings/1y · 3 PIPEs
  • 2026-07-17EFFECTshelf_effective
  • 2026-07-10S-3shelf_registration
  • 2026-06-188-Kprivate_placement
  • 2026-06-108-Kmaterial_agreement
  • 2026-06-09424B5offering
  • 2026-06-05424B5offering
  • 2026-05-228-Kmaterial_agreement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $17 (+1580% upside) · 5 analysts
  • 2026-04-20D. Boral CapitalBuy → Hold
  • 2026-04-02HC Wainwright & Co.Buy
  • 2026-03-31D. Boral CapitalBuy
  • 2026-03-26D. Boral CapitalBuy
  • 2026-03-18D. Boral CapitalBuy
  • 2026-01-21D. Boral CapitalBuy

Competitors

  • none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.